...
首页> 外文期刊>BioSocieties >Medical innovation and national experimental pluralism: Insights from clinical stem cell research and applications in China
【24h】

Medical innovation and national experimental pluralism: Insights from clinical stem cell research and applications in China

机译:医学创新与国家实验多元性:中国临床干细胞研究与应用的启示

获取原文
获取原文并翻译 | 示例
           

摘要

The article focuses on the integration process of clinical stem cell research in China in the international arena of high-profile science. This development is analyzed against the background of a well-established landscape of informal and frequently for-profit forms of clinical experimentation with stem cells. In doing so, I trace the institutionalization of experimental clinical stem cell research and applications in China, its stepwise problematization and metamorphosis into an object of regulatoryconcern and intervention. It will become clear that the transition toward adoption of an internationally recognized standard system in the clinical stem cell field is a complex and highly contested process. The long-standing absence of a coherent state-centered regulatory approach for clinical stem cell research and applications in China has not only given rise to the realization of new economic opportunities, but also to a multi-stranded innovation culture, which is characterized by knowledge exchanges and collaborations between highly diverging socio-technical and epistemic communities. I will make sense of these processes through the concept of 'national experimental pluralism'.
机译:本文重点关注国际上备受瞩目的科学领域中中国临床干细胞研究的整合过程。在发展良好的非正式和经常以营利为目的的干细胞临床试验形式的背景下分析了这一发展。在此过程中,我追踪了中国临床干细胞研究和应用的制度化,逐步的问题化和变态成为监管关注和干预的对象。显然,在临床干细胞领域向采用国际认可的标准体系的过渡是一个复杂且竞争激烈的过程。长期以来缺乏在中国进行临床干细胞研究和应用的以国家为中心的统一监管方法,不仅带来了新的经济机会的实现,而且还带来了以知识为特征的多链创新文化高度不同的社会技术和认知社区之间的交流与合作。我将通过“国家实验多元化”的概念来理解这些过程。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号